LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
4 d agoKey statistics
4 d ago- Market cap
- $1.06T
- Enterprise value
- $1.10T
- P/E (TTM)
- 41.85
- Forward P/E
- 24.92
- P/E (annual)
- 51.25
- PEG
- 1.29
- P/B
- 38.29
- P/S (TTM)
- 14.64
- P/S (annual)
- 16.23
- EV / EBITDA
- 32.65×
- EV / Revenue
- 15.17×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.61%
- Dividend yield (TTM)
- 0.53%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.53
- Volatility (3M)
- 37.23%
Analyst ratings
4 d agoEarnings
4 d agoRelated news
4 d ago- Yahoo·6 d agocompanyKailera’s three-pronged obesity shot shows promise in early trial
As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
- SeekingAlpha·6 d agocompanySouth Korea: Asia's Second Innovation Engine
South Korea has been the second most important contributor to the growth of Asian innovation in recent years, outperforming Japan in several areas. Read more here.
- CNBC·6 d agocompanyHealthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
- CNBC·6 d agocompanyBMO's Evan Seigerman on GLP-1 developments, state of weight-loss drug battle
Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Squawk Box' to discuss the state of the pharma sector, latest GLP-1 developments, weight-loss drug market competition, and more.
- Yahoo·6 d agocompanyLilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree
The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly's recently published study.
- Yahoo·6 d agocompanyMicron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next.
Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.
- Yahoo·6 d agocompanyHow The Eli Lilly (LLY) Narrative Is Evolving With GLP-1 Hopes And Obesity Market Doubts
Eli Lilly's fair value estimate has shifted slightly from US$1,209.21 to US$1,211.03 per share, a small move that still reflects meaningful debate around what is already priced into the stock. Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded. As you read on, you will see how these competing views shape the evolving narrative around...
